CardioVascular Center for Research and Innovation (CVCRI)

Achievements + Innovation

Marvin Konstam, MD was honored with the HFSA Lifetime Achievement AwardHFSA Lifetime Achievement Award

Congratulations to CardioVascular Center Chief Physician Executive Marvin Konstam, MD on receiving the highly prestigious 2018 Lifetime Achievement Award from the Heart Failure Society of America - HFSA. Dr. Konstam will be presented with the award at the HFSA's 22nd Annual Scientific Meeting being held in Nashville, TN this September 15-18.

 


500th Heart transplant

Marvin Konstam, MD and Deeb Salem, MD at the first heart transplant at Tufts MCOn June 6, Tufts Medical Center reached a landmark milestone in cardiac transplantation when the Advanced Heart Failure + Cardiac Transplant Program, under the direction of David DeNofrio, MD, performed its 500th heart transplant at Tufts MC. The patient, Frank Lalli, 61, from Portsmouth, RI, is recovering well from the procedure. Since 2000, Tufts MC has performed more heart transplants in New England than any other hospital in the region. In 2016, Tufts MC completed 56 heart transplants, a New England record that ranked among the top-10 heart transplant programs in the country for volume. Learn more about this milestone >

A large group of physicians standing in the shape of a heart35th Anniversary- Cardiac Arrhythmia Center

The 2018 Criscitiello Lecture featured speaker Thomas Deering, MD, MBA.



Dr. Munther Homoud received the Leonard Tow Humanism in Medicine Leonard Tow Humanism in Medicine Award

Sponsored and administered by The Gold Foundation. In recognition of graduating students and faculty members who demonstrate both clinical excellence and outstanding compassion in the delivery of care and who show respect for patients, their families, and healthcare colleagues.

Natalie Zucker Prize Winners

From the The Natalie V. Zucker Research Center for Women Scholars, devoted to furthering the research careers of female basic and clinical scientists at Tufts University School of Medicine and Sackler School of Graduate Biomedical Sciences.

  • Lija Swain, PhD - Basic Science
  • Mehak Dhande, MD - CardioVascular Fellow

New Facilities

Learn more about our newly renovated Cardiac Catherization lab, Hypertrophic Cardiomyopathy Center and ElectroPhysiology Lab >

 
 

Investigator

Funding Source

Title of Project

Robert Blanton, MD

NIH

Novel Protein Kinase GI Substrates in Cardiac Remodeling and Blood Pressure Control

NIH (sub from Tufts University)

Cardiac Cell Entry-Inhibition and Protection Therapy for Chronic Chagas Disease

Industry

Pre-clinical Study

Industry

Pre-clinical Study

Michael Chin, MD, PhD

NIH

Intracellular mitochondrial enzyme replacement therapy for heart and skeletal myopathy in Barth Syndrome

Gordon Huggins, MD

NIH (sub from UCONN)

Salivary Amylase Gene (AMY 1) as Predictor of Weight and Diet in LookAhead & DPP

Tufts University Russo Award

Diagnosis of Heart Failure Status using Metabolomics

Iris Jaffe, MD, PhD

American Heart Association

Extra-Renal Mineralocorticoid Receptors in Hypertension

NIH

The Role of Vascular MR-Regulated Genes in Vascular Function and Disease

NIH

Smooth Muscle Mineralocorticoid Receptors in Vascular Aging and Hypertension

NIH (sub from Michigan State University)

Cerebral parenchymal arteriole dysfunction and cognitive decline in a life-long high fat feeding model

NIH (sub from University of Missouri)

Mineralocorticoid receptor-dependent coronary vascular dysfunction in obesity

NIH (sub from University of Missouri)

Mechanisms for Sex Differences in CVD Pathology and Development of a Targeted Therapeutic

Iris Jaffe, MD, PhD/Robert Blanton, MD

Industry

Pre-clinical Study

Navin Kapur

Industry Pre-clinical study

NIH

Endoglin: A New Target of Therapy for Heart Failure

NIH

Mechanical Unloading and Delayed Reperfusion Promotes Myocardial Recovery after Acute Myocardial Infarction

Industry

Pre-clinical Study


Investigator

Funding Source

Title of Project

David DeNofrio, MD

NIH

CTOT-11 Long-term Safety Follow-up

N.A. Mark Estes, MD

NIH

Genetics, Mechanisms and Clinical Phenotypes of Arrhythmogenic Cardiomyopathy

NIH

Late Sodium current blockade in high-risk ICD patients

Gordon Huggins, MD

NIH

Heart Failure Network: New England, New York and Quebec Regional Clinical Center

NIH

Precision Medicine for Dilated Cardiomyopathy in European and African Ancestry

NIH (Heart Failure Network)

Characterizing HIV-related Diastolic Dysfunction

NIH (Heart Failure Network)

Subcutaneous Furosemide in Acute Decompensated Heart Failure –SUBQ-HF

Mark Iafrati, MD

Industry

Treatment of Critical LimB IschemIa (CLI) in Subjects with Severe Peripheral ArteriaL Disease (PAD) 

Industry

A Phase II Clinical Study of a new treatment for Patients with Infrarenal Abdominal Aortic Aneurysms

Industry

A Prospective, Randomized, Open Label Clinical Proof of Concept Study to Assess the Performance of an Antimicrobial Wound Gel in Subjects with Diabetic Foot Ulcers

Industry

An Evaluation of the Safety Performance of a new approach to Wound Dressing

Industry

A Prospective, Randomized, Open Label Clinical Proof of Concept Study to Assess the Performance of a new Antimicrobial Wound Dressing in Subjects with Venous Leg Ulcers

Industry

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of a new treatment for Subjects with Critical Limb Ischemia (CLI) with Minor Tissue Loss who are Unsuitable for Revascularization (PACE Study)

Navin Kapur, MD

Abbott

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (The COAPT Trial)

Abiomed

Door To Unloading with IMPELLA CP® System in Acute Myocardial Infarction to Reduce Infarct Size (DTU): A Prospective Feasibility Study

Abiomed

CVAD Registry

Abiomed

RECOVER RIGHT: The Use of Impella RP Support System in Patients with Right Heart Failure: Post Approval Study

Henry Ford Health System

National Cardiogenic Shock Initiative (NCSI)

Thoratec

Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Michael Kiernan, MD

 

 

NIH (sub from Northwestern)

Mechanical circulatory support: Measures of adjustment and quality of life

NIH

Heart Failure Clinical Research Network:

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Heartware

A Prospective, Single Arm, Multi-Center Clinical Study in Collaboration with the InterAgency Registry for Mechanically Assisted Circulatory Support (INTERMACS®) to Evaluate the Thoracotomy Implant Technique of the HeartWare HVAD® System in Patients with Advanced Heart Failure

Heartware

A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System for Destination Therapy of Advanced Heart Failure

Heartware

A Multi Center, Post Approval Study Providing Continued Evaluation and Follow-up on Patients

Who Received a HeartWare® Ventricular Assist System During IDE Trials for the Treatment of Advanced Heart Failure

Carey Kimmelstiel, MD

Boston Scientific

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGYTM Stent System) for the Treatment of Atherosclerotic Lesion(s)

Boston Scientific

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Cardiovascular Systems, Inc.

Multi-center Prospective Study to Evaluate Outcomes of Moderate to Severely Calcified Coronary Lesions (MACE)

Eisai Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Lilly

The effect of prasugrel therapy as compared to clopidogrel on platelet function immediately following the termination of intravenous bivalirudin therapy in patients undergoing percutaneous coronary and structural cardiac intervention

 MD Start First in man proof of concept clinical ctudy for heart failure

Sanofi Pharmaceuticals

A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients who have Recently Experienced an Acute Coronary Syndrome (Odyssey).

Martin Maron, MD

NIH (sub from ICON)

HCMR- Novel Predictors of Outcome in Hypertrophic Cardiomyopathy

NIH (sub from Yale)

Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy "LIVE-HCM"/Lifestyle and Exercise in the Long QT Syndrome "LIVE-LQTS

Gilead Sciences

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Ayan Patel, MD

Alnylam Pharmaceuticals

Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Alnylam Pharmaceuticals

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Payem Salehi, MD

Bolton Medical

A Prospective, Multicenter, Non-blinded, Non-randomized Study of the Relay PRO Thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

Jenica Upshaw, MD

Merck

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Amanda Vest, MBBS, MPH

American Heart Association

Scientist Development Grant

Actelion

A prospective, multicenter, double-blind, randomized, placebo-controlled parallel – group study to assess the efficacy and safety of macitentan in patients with pulmonary hypertension after left ventricular assist device implantation

Boehringer-Ingelheim

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)

Boehringer-Ingelheim

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)

Corvia Medical, Inc.

REDUCE LAP-HF RANDOMIZED TRIAL II: A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

Tufts University Charlton Award

The Metabolomic Profile of Advanced Systolic Heart Failure and Changes with Metabolic Recovery after Ventricular Assist Device Implantation

Jonathan Weinstock, MD

UCSF

Vest Prevention of Early Sudden Death Trial (VEST) and VEST Registry

St Jude Medical

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT)

St Jude Medical

Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker

Andrew Weintraub, MD

Cardiovascular Research Foundation

TAVR UNLOAD